Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8.125 ^USD	-1.16%		-3.85%	+121.99%

May. 13	Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	MT
May. 08	Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024

Mind Medicine Inc. Announces Transitions to Management Team

December 29, 2021 at 08:00 am EST

Mind Medicine (MindMed) Inc. announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. Additionally, Don Gehlert, PhD will be transitioning from his role as CSO and will continue as a Senior Scientific Advisor.

Latest news about Mind Medicine (MindMed) Inc.

Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	May. 13	MT
Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target	Apr. 15	MT
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital	Mar. 17	CI
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk	Mar. 08	MT
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder	Mar. 08	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Mar. 07	MT
Sector Update: Health Care Stocks Stronger in Afternoon Trading	Mar. 07	MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating	Mar. 07	MT
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump	Mar. 07	MT
Transcript : Mind Medicine Inc. - Special Call	Mar. 07
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder	Mar. 07	CI
Mind Medicine Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital	Mar. 06	CI
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept	Feb. 29	MT
Transcript : Mind Medicine Inc., 2023 Earnings Call, Feb 28, 2024	Feb. 28
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024	Jan. 08	CI
Mind Medicine Says MM-120 Shows Significant Dose-Dependent Improvements in Phase 2b Trial on Anxiety Disorder	Dec. 14	MT
Transcript : Mind Medicine Inc. - Special Call	Dec. 14
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	Dec. 14	CI
Transcript : Mind Medicine Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder	23-10-24	CI

Chart Mind Medicine (MindMed) Inc.

Duration

Period

More charts

Company Profile

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

Calendar

2024-06-10 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.125 USD

Average target price

23.86 USD

Spread / Average Target

+193.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIND MEDICINE (MINDMED) INC.	+121.99%	591M
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research